Eli Lilly and Company (NYSE:LLY) Shares Bought by Relyea Zuckerberg Hanson LLC

Relyea Zuckerberg Hanson LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,033 shares of the company’s stock after acquiring an additional 323 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Eli Lilly and Company were worth $2,342,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CNB Bank grew its holdings in shares of Eli Lilly and Company by 10.1% during the fourth quarter. CNB Bank now owns 1,255 shares of the company’s stock worth $969,000 after buying an additional 115 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $2,316,000. Procyon Advisors LLC grew its holdings in shares of Eli Lilly and Company by 11.9% during the fourth quarter. Procyon Advisors LLC now owns 3,942 shares of the company’s stock worth $3,043,000 after buying an additional 419 shares in the last quarter. Everpar Advisors LLC grew its holdings in shares of Eli Lilly and Company by 0.6% during the fourth quarter. Everpar Advisors LLC now owns 2,680 shares of the company’s stock worth $2,069,000 after buying an additional 17 shares in the last quarter. Finally, Tompkins Financial Corp increased its position in shares of Eli Lilly and Company by 7.4% in the fourth quarter. Tompkins Financial Corp now owns 33,270 shares of the company’s stock worth $25,684,000 after acquiring an additional 2,288 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LLY shares. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price for the company. Bank of America restated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Trading Down 4.1 %

Eli Lilly and Company stock opened at $726.24 on Friday. The firm’s 50-day moving average is $781.14 and its 200-day moving average is $854.71. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 1 year low of $612.70 and a 1 year high of $972.53. The company has a market cap of $689.43 billion, a P/E ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The company’s quarterly revenue was up 20.4% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post 13.14 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company declared that its board has approved a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.